Advertisement

Topics

Johnson and Johnson (France) Company Profile

05:12 EDT 29th June 2016 | BioPortfolio

Our pharmaceuticals companies offer medicines that treat many of the world's most serious and widespread diseases. These diseases range from cancer, HIV/AIDS and bacterial infections to schizophrenia, epilepsy, rheumatoid arthritis and psoriasis. In 2007, we invested $5.3 billion in the search for new ways to treat these diseases and many others. It’s all part of our commitment to helping you and the ones you love lead longer, healthier lives.

These companies are organized into three global business units:

Central Nervous System and Internal Medicine

This business unit develops medicines for an array of health problems, including central nervous system disorders, such as schizophrenia and epilepsy; metabolic diseases, such as diabetes; cardiovascular diseases; and infectious diseases.

B.I.O. (Biotechnology, Immunology & Oncology)

This business unit develops traditional and biologic medicines to treat autoimmune disorders, such as rheumatoid arthritis, psoriasis, and Crohn’s disease; a wide range of cancers; and blood disorders, such as anemia.

Virology

This business unit develops medicines for the treatment of infectious diseases, such as HIV/AIDS, hepatitis C and tuberculosis.

Location

rue camille desmoulins
issy les moulineaux cedex 9
F-92787
France

Contact

Phone: 33-155004174


News Articles [1563 Associated News Articles listed on BioPortfolio]

M&As this week: Johnson & Johnson, DNA2.0

Johnson & Johnson has announced its plans to acquire Neostrata, its affiliates and Tristrata Incorporated.

Johnson & Johnson 4th-qtr beats expectations

US health care giant Johnson & Johnson kicked off the fourth-quarter 2015 financial results reporting…

BRIEF-Johnson & Johnson says collaborating with HP Inc's unit

* Johnson & Johnson announces collaboration with HP Inc. subsidiary to create personalized health care solutions with 3D printing technologies

BRIEF-Johnson & Johnson reports Q1 EPS of $1.54

April 19 (Reuters) - Johnson & Johnson Says Increased Its Adjusted Earnings Guidance For Full

Pharmalot, Pharmalittle: Johnson & Johnson to pay $498M over hip implant injuries

Johnson & Johnson was ordered by a Texas federal jury to pay $490 million to five plaintiffs who claimed they were injured by the company's hip implants.

Johnson & Johnson: The Fundamentals of Alliance Management

Johnson & Johnson were one of the first companies to realise the importance of an alliance management group closely following in rival Eli Lilly & Co.’s footsteps. Rob Wills, VP Alliance Management ...

Johnson & Johnson - Product Pipeline Review - 2016

Johnson & Johnson - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Johnson & Johnson - Product Pipeline Review - 2016’, provides an overview of the Johnson & John...

Johnson & Johnson Innovation to provide new funding and support for European research companies

US health care giant Johnson & Johnson (NYSE: JNJ), through its J&J Innovation unit, has launched JLINX,…

PubMed Articles [290 Associated PubMed Articles listed on BioPortfolio]

Incidence of Stevens-Johnson Syndrome and Chemical Burns to the Eye.

This population-based observational study was designed to estimate the incidence and distribution of SJS-spectrum (Stevens-Johnson syndrome, toxic epidermal necrolysis, and toxic epidermal Necrolysis/...

Reformulation of the D3(Becke-Johnson) Dispersion Correction without Resorting to Higher than C6 Dispersion Coefficients.

A reformulated version of Grimme's most recent DFT dispersion correction with Becke-Johnson damping (DFT-D3(BJ)) is presented, which only depends on C6 dispersion coefficients. The role of the higher ...

Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women.

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) form a spectrum of a rare and life-threatening cutaneous drug reaction. SJS/TEN in pregnancy poses largely unknown risk factors and ...

Chronic Conditions: Beckett, Bergson and Samuel Johnson.

This article analyses the work of the twentieth-century late modernist Samuel Beckett, in light of the turn-of-the-century anti-rationalist Henri Bergson (1859-1941) and the eighteenth-century neoclas...

Stevens Johnson syndrome-Toxic Epidermal Necrolysis Overlap induced by sulfasalazine treatment: a case report.

Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening and severe adverse cutaneous drug reactions characterized by epidermal detachment presenting as blisters and ar...

Clinical Trials [293 Associated Clinical Trials listed on BioPortfolio]

Stevens-Johnson Syndrome Antimicrobial

Steven-Johnson's syndrome, or great multiform erythema, appears as a systemic disturbance, with skin involvement and mucous membranes, related to several factors, such as, viral or bacteri...

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion crit...

Extracorporeal Photopheresis Pilot Study

ECP will be given to the patients [UVAR®XTS TM Therakos system, Johnson & Johnson] according to the following schedule: Starting at day 21 after transplant, if hematologic recovery allow...

A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition

The study was conducted as an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets, USP 20 ...

A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition

The study was conducted as an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets, USP 20 ...

Companies [465 Associated Companies listed on BioPortfolio]

Johnson and Johnson

Johnson & Johnson, employing approximately 119,000 people worldwide, is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. Johnso...

Johnson & Johnson Innovation

The London Innovation Centre is part of Johnson & Johnson Innovation, a division of Johnson & Johnson Finance Limited. Johnson & Johnson Innovation focuses on accelerating early i...

Johnson & Johnson (China) Investment Co., Ltd.

Johnson & Johnson (China) Investment Co., Ltd. is a foreign investment entity established in China by Johnson & Johnson in 1998. For more information about Johnson & Johnson and its operating unit...

JOHNSON'S(R) Brand

JOHNSON'S® Brand from Johnson & Johnson Consumer Products Company, Division of Johnson & Johnson Consumer Companies, Inc., has a long tradition of providing pure, mild, gentle and clinically-proven p...

JANSSEN-ORTHO INC

Since 1961 Janssen-Cilag has been a member of the Johnson & Johnson family of companies. Founded in 1886, Johnson & Johnson today is the world's most comprehensive manufacturer of healthcare products ...

More Information about "Johnson and Johnson (France)" on BioPortfolio

We have published hundreds of Johnson and Johnson (France) news stories on BioPortfolio along with dozens of Johnson and Johnson (France) Clinical Trials and PubMed Articles about Johnson and Johnson (France) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Johnson and Johnson (France) Companies in our database. You can also find out about relevant Johnson and Johnson (France) Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...


Corporate Database Quicklinks



Searches Linking to this Company Record